Cargando…
Pneumococcal conjugate vaccine 13 delivered as one primary and one booster dose (1 + 1) compared with two primary doses and a booster (2 + 1) in UK infants: a multicentre, parallel group randomised controlled trial
BACKGROUND: Infants in the UK were first offered a pneumococcal conjugate vaccine (PCV7) in 2006, given at 2 and 4 months of age and a booster dose at 13 months (2 + 1 schedule). A 13-valent vaccine (PCV13) replaced PCV7 in 2010. We aimed to compare the post-booster antibody response in UK infants g...
Autores principales: | Goldblatt, David, Southern, Jo, Andrews, Nick J, Burbidge, Polly, Partington, Jo, Roalfe, Lucy, Valente Pinto, Marta, Thalasselis, Vasilli, Plested, Emma, Richardson, Hayley, Snape, Matthew D, Miller, Elizabeth |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Science ;, The Lancet Pub. Group
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5805912/ https://www.ncbi.nlm.nih.gov/pubmed/29174323 http://dx.doi.org/10.1016/S1473-3099(17)30654-0 |
Ejemplares similares
-
Immunogenicity of a single-dose compared with a two-dose primary series followed by a booster dose of ten-valent or 13-valent pneumococcal conjugate vaccine in South African children: an open-label, randomised, non-inferiority trial
por: Madhi, Shabir A, et al.
Publicado: (2020) -
Assignment of Serotype-Specific IgG1, IgG2, and IgA Weight-Based Antibody Units to the Human Pneumococcal Standard Reference Serum, 007sp
por: Jones, Scott, et al.
Publicado: (2019) -
Immunogenicity of Simulated PCECV Postexposure Booster Doses 1, 3, and 5 Years after 2-Dose and 3-Dose Primary Rabies Vaccination in Schoolchildren
por: Kamoltham, Thavatchai, et al.
Publicado: (2011) -
Booster Doses and Prioritizing Lives Saved
por: Patel, Minal K.
Publicado: (2021) -
COVID-19 vaccine equity and booster doses
por: The Lancet Infectious Diseases
Publicado: (2021)